Meclizine Hydrochloride

MECLIZINE HYDROCHLORIDE- meclizine hydrochloride tablet
Watson Laboratories, Inc.

DESCRIPTION

Meclizine HCl, an oral antiemetic, is a white, slightly yellowish, crystalline powder which has a slight odor and is tasteless. It has the following structural formula:

Image from Drug Label Content
(click image for full-size original)

C25 H27 CIN2 .2HCl.H2 O  481.89

The chemical name is 1-(p -chloro-α-phenylbenzyl)-4-(m -methylbenzyl) piperazine dihydrochloride monohydrate.

Each tablet, for oral administration, contains 12.5 mg or 25 mg of Meclizine HCl. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, corn starch, D&C yellow # 10 lake (25 mg only), FD&C blue # 1 lake (12.5 mg only), lactose monohydrate, microcrystalline cellulose, povidone (12.5 mg only), sodium starch glycolate, and stearic acid.

ACTIONS

Meclizine HCl is an antihistamine which shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum. It has a slower onset and longer duration of action (24 hours) than most other antihistamines used for motion sickness.

Antihistamines have been observed to have both stimulant and depressant effects on the CNS, but no clear explanation exists in regard to their diverse central actions. The site and mode of their central action is unknown.

INDICATIONS:

Prophylactic treatment and management of nausea and vomiting, and dizziness associated with motion sickness.

CONTRAINDICATIONS

Meclizine HCl is contraindicated in individuals who have shown a previous hypersensitivity to it.

WARNINGS

Some drowsiness may, on occasion, occur with the use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.

Patients should avoid alcoholic beverages while taking this drug. Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland.

USAGE IN PEDIATRIC PATIENTS

Clinical studies establishing safety and effectiveness in pediatric patients have not been done; therefore, usage is not recommended in pediatric patients under 12 years of age.

USAGE IN PREGNANCY

Pregnancy Category B. Reproduction studies in rats have shown cleft palates at 25-50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that meclizine increases the risk of abnormalities when administered during pregnancy. Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine, or any other medication, should be used during pregnancy only if clearly necessary.

Adverse Reactions to Meclizine Hydrochloride

Drowsiness, dry mouth, and on rare occasions, blurred vision have been reported.

DOSAGE AND ADMINISTRATION

Motion Sickness: The initial dose of 25 to 50 mg of meclizine, should be taken prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.

HOW SUPPLIED

Meclizine HCl Tablets USP are supplied as follows:

12.5 mg: Blue/white, oval, bi-layer tablet debossed WATSON and 802 on one side and a partial bisect on the other side, in bottles of 100.

25 mg: Yellow/white, oval, bi-layer tablet debossed WATSON and 803 on one side and a partial bisect on the other side, in bottles of 100 and 1000.

Store at controlled room temperature 15°-30°C (59°- 86°F). Dispense in a well-closed container as defined in USP/NF.

Manufactured For:
Watson Laboratories, Inc.
Corona, CA 92880 USA

Manufactured by:
Patheon Pharmaceuticals Inc.
Cincinnati, OH 45215 USA

Rev. 10/03
70010599

MECLIZINE HYDROCHLORIDE
meclizine hydrochloride tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0591-0803
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Meclizine Hydrochloride (Meclizine) Meclizine 25 mg
Inactive Ingredients
Ingredient Name Strength
collidiol silicon dioxide
corn starch
D & C Yellow #10 lake
lactose monohydrate
microcrystalline cellulose
sodium starch glycolate
stearic acid
Product Characteristics
Color WHITE (white) , YELLOW (yellow) Score no score
Shape OVAL Size 13mm
Flavor Imprint Code WATSON;803
Contains
Coating false Symbol false
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0591-0803-01 100 TABLET (100 TABLET) in 1 BOTTLE None
2 NDC:0591-0803-10 1000 TABLET (1000 TABLET) in 1 BOTTLE None
MECLIZINE HYDROCHLORIDE
meclizine hydrochloride tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0591-0802
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Meclizine Hydrochloride (Meclizine) Meclizine 12.5 mg
Inactive Ingredients
Ingredient Name Strength
collidiol silicon dioxide
corn starch
FD & C Blue #1 lake
lactose monohydrate
microcrystalline cellulose
povidone
sodium starch glycolate
stearic acid
Product Characteristics
Color BLUE (Blue) , WHITE (white) Score no score
Shape OVAL Size 13mm
Flavor Imprint Code WATSON;802
Contains
Coating false Symbol false
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0591-0802-01 100 TABLET (100 TABLET) in 1 BOTTLE None
Labeler — Watson Laboratories, Inc.

Revised: 03/2006 Watson Laboratories, Inc.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.